Furthermore, combination therapy with alisertib and B7-H3–specific blocking mAbs resulted in increased infiltration of CD8+ cells into the tumor microenvironment, providing a potential treatment strategy for malignant GBM. The gene discussed is CD8A; the disease is glioblastoma.